Activity of Mefloquine Against Urinary Schistosomiasis

• Status: Completed
• Trial end date: 2012-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

Urinary schistosomiasis is a debilitating disease in Central Africa and pregnant women are frequently suffering from this condition. Mefloquine is currently investigated as preventive treatment against malaria in pregnancy and mefloquine is also known to exert activity against schistosomiasis. The investigators want to test the hypothesis whether mefloquine may active against urinary schistosomiasis when used as preventive treatment against malaria in pregnancy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Albert Schweitzer Hospital
• Treatments: Fanasil, pyrimethamine drug combination; Mefloquine

Criteria

Inclusion Criteria:

• Pregnant women after first trimester and before 28th week of pregnancy

• HIV negative

• Egg excretion of Schistosoma haematobium (mean >10 eggs per mL urine)

• Asymptomatic (no signs of complicated Schistosomiasis, no severe anemia)

• Ability to comply with study protocol

Exclusion Criteria:

• Intake of anthelminthic or antimalarial drug within 2 months prior to inclusion

• Allergy to study drugs